 Connection
Matthew Witkowski to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Matthew Witkowski has written about Xenograft Model Antitumor Assays.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.280 |
|
|
|
-
Garcia C, Lyons KU, Contreras JG, Liu T, Donnelly AJ, Novak AJ, Argabright A, Anderson C, Grier A, Smith S, Michlin J, Olusoji J, Mikeska RG, Zhou X, Geng H, Rahkola JT, Patel HN, Jacot JG, Müschen M, D'Alessandro A, Dick JE, Iacobucci I, Mullighan CG, Reisz JA, Phang T, Eric Kohler M, Witkowski MT. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. Leukemia. 2026 Aug; 40(8):1763-1777.
Score: 0.191
-
La Vecchia S, Doshi S, Antonoglou P, Kundu T, Al Santli W, Avrampou K, Witkowski MT, Pellattiero A, Magrin F, Ames K, Verma A, Gritsman K, Su X, Mattarei A, Aifantis I, Scorrano L, Glytsou C. Small-molecule OPA1 inhibitors reverse mitochondrial adaptations to overcome therapy resistance in acute myeloid leukemia. Sci Adv. 2025 Oct 17; 11(42):eadx8662.
Score: 0.045
-
Ma J, Wang Z, Mintzlaff D, Zhang H, Ramakrishna R, Davila E, Witkowski MT, Lucia MS, Schwartz MS, Pomfret EA, Mathes DW, Wang Z. Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia. Blood. 2025 01 30; 145(5):508-519.
Score: 0.043
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|